The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration-Reference-Cited by-同舟云学术

The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration

Published:2011-04-27 Issue:1 Volume:11 Page:
ISSN:1471-2490
Container-title:BMC Urology
language:en
Short-container-title:BMC Urol

Author:

Tanaka Nobumichi,Fujimoto Kiyohide,Hirayama Akihide,Samma Shoji,Momose Hitoshi,Kaneko Yoshiteru,Haramoto Masaki,Hayashi Yoshiki,Nakagawa Yoshinori,Otani Takeshi,Watanabe Shuji,Hirao Yoshihiko

Publisher

Springer Science and Business Media LLC

Subject

Urology,Reproductive Medicine,General Medicine

Link

http://link.springer.com/article/10.1186/1471-2490-11-6/fulltext.html

Reference15 articles.

1. Cooperberg MR, Lubeck DP, Penson DF, Mehta SS, Carroll PR, Kane CJ: Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol. 2003, 170 (3): 905-908. 10.1097/01.ju.0000081200.63275.0b.

2. Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y: Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol. 2010, 40 (6): 588-592. 10.1093/jjco/hyq008.

3. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007, 178 (3 Pt 2): S14-19.

4. Krupski TL, Kwan L, Afifi AA, Litwin MS: Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol. 2005, 23 (31): 7881-7888. 10.1200/JCO.2005.08.755.

5. Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA: Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010, 28 (6): 1069-1074. 10.1200/JCO.2009.26.2469.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015;International Journal of Urology;2021-08-05

2. Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012;BMC Cancer;2017-09-02

3. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute;BMC Urology;2017-08-14

4. Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases;Journal of Contemporary Brachytherapy;2017

5. Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer;Radiotherapy and Oncology;2015-06